A decade of fragment-based drug design: strategic advances and lessons learned

[1]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[2]  Stephen K. Burley,et al.  Fragment‐based Lead Discovery and Optimization Using X‐Ray Crystallography, Computational Chemistry, and High‐throughput Organic Synthesis , 2006 .

[3]  Maurizio Pellecchia,et al.  Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid , 2006, Proceedings of the National Academy of Sciences.

[4]  Mark Whittaker,et al.  Fragment screening by biochemical assay , 2006, Expert opinion on drug discovery.

[5]  W. Wolfson.  Fragmentary solutions. Astex therapeutics puts the pieces together. , 2006, Chemistry & biology.

[6]  D. V. Von Hoff,et al.  Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.

[7]  G. Scapin,et al.  Structural biology and drug discovery. , 2006, Current pharmaceutical design.

[8]  Sandor Vajda,et al.  Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.

[9]  Ricardo Macarron,et al.  Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.

[10]  Alexander Hillisch,et al.  Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.

[11]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[12]  Simona Golic Grdadolnik,et al.  In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[13]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[14]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[15]  K. Ziegelbauer,et al.  Genomics: success or failure to deliver drug targets? , 2005, Current opinion in chemical biology.

[16]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[17]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[18]  Dawoon Jung,et al.  Efficient synthetic inhibitors of anthrax lethal factor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[20]  E. Butcher.  Can cell systems biology rescue drug discovery? , 2005, Nature Reviews Drug Discovery.

[21]  Peter Meier,et al.  Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. , 2005, Current topics in medicinal chemistry.

[22]  Andrew M Davis,et al.  Components of successful lead generation. , 2005, Current topics in medicinal chemistry.

[23]  Joni W. Lam,et al.  Structural analysis of caspase-1 inhibitors derived from Tethering. , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.

[24]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[25]  Jean-Louis Reymond,et al.  Virtual exploration of the small-molecule chemical universe below 160 Daltons. , 2005, Angewandte Chemie.

[26]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[27]  Gregg Siegal,et al.  TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. , 2005, Chemistry & biology.

[28]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[29]  Renaldo Mendoza,et al.  ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. , 2005, Journal of the American Chemical Society.

[30]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[31]  Tudor I. Oprea,et al.  Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.

[32]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[33]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[34]  J. R. Huth,et al.  Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. , 2004, Analytical biochemistry.

[35]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[36]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[37]  Jean M. Severin,et al.  Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.

[38]  L. Hardy,et al.  The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. , 2004, Drug discovery today.

[39]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[40]  Nicola Mongelli,et al.  A general NMR method for rapid, efficient, and reliable biochemical screening. , 2003, Journal of the American Chemical Society.

[41]  E. Mandine,et al.  Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. , 2003, Journal of medicinal chemistry.

[42]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[43]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[44]  Thomas Peters,et al.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. , 2003, Angewandte Chemie.

[45]  P. Hajduk,et al.  Integration of NMR and high-throughput screening. , 2002, Combinatorial chemistry & high throughput screening.

[46]  Daniel A Erlanson,et al.  Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. , 2002, Journal of medicinal chemistry.

[47]  J. Sanders,et al.  Recent developments in dynamic combinatorial chemistry. , 2002, Current opinion in chemical biology.

[48]  Stefan Knapp,et al.  NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands. , 2002, Journal of medicinal chemistry.

[49]  Jean-Pierre Marquette,et al.  SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.

[50]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[51]  Yan Guo,et al.  Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. , 2002, Journal of medicinal chemistry.

[52]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[53]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[54]  A V Eliseev,et al.  Dynamic Combinatorial Chemistry , 2001, Science.

[55]  E B Reilly,et al.  Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. , 2001, Journal of medicinal chemistry.

[56]  Jean M. Severin,et al.  Design of adenosine kinase inhibitors from the NMR-based screening of fragments. , 2000, Journal of medicinal chemistry.

[57]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[58]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[59]  R. London,et al.  Theoretical analysis of the inter-ligand overhauser effect: a new approach for mapping structural relationships of macromolecular ligands. , 1999, Journal of magnetic resonance.

[60]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[61]  P. Hajduk,et al.  NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.

[62]  B. Stockman.  NMR spectroscopy as a tool for structure-based drug design , 1998 .

[63]  J. Broach,et al.  New assay technologies for high-throughput screening. , 1998, Current opinion in chemical biology.

[64]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[65]  Mengfen Lin,et al.  Diffusion-Edited NMR−Affinity NMR for Direct Observation of Molecular Interactions , 1997 .

[66]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[67]  Y. Martin,et al.  Challenges and prospects for computational aids to molecular diversity , 1996 .

[68]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[69]  Hans-Joachim Böhm,et al.  Site-directed structure generation by fragment-joining , 1995 .

[70]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[71]  Jeffrey W. Peng,et al.  Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design. , 2004, Journal of synchrotron radiation.

[72]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[73]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .